Clinical Research Directory
Browse clinical research sites, groups, and studies.
CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
Sponsor: Navy General Hospital, Beijing
Summary
The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.
Official title: CHG Regimen Combined With Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
85
Start Date
2024-09-20
Completion Date
2028-12
Last Updated
2024-08-22
Healthy Volunteers
No
Conditions
Interventions
CHG Combined With Venetoclax and Azacytidine
Patients were treated by CHG Combined With Venetoclax and Azacytidine: Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7; Homoharringtonine 1mg/m2 iv qd d1-14; Cytarabine 10mg/m2 subcutaneous injection q12h d1-14; G 250ug/m2 subcutaneous injection qd d0-14.
Locations (1)
Navy General Hospital
Beijing, Beijing Municipality, China